Search Follow us

Derma Sciences (DSCI)

Business description

Derma Sciences is a wound-care focussed firm, with lead candidate DSC127 in Phase III trials for DFUs. Derma also manufactures and markets branded advanced wound care (AWC) products, and traditional wound care (TWC) products (eg. basic dressings and gauzes).

Complete wound care

Initiation | Pharmaceutical & healthcare | 19/09/2013

Using cash generated from the slow-growing but stable traditional wound care business unit, Derma Sciences was able to invest in its advanced wound care unit, which has seen an annual growth rate of 40-55%. The company has also started a Phase III trial of DSC127, a drug developed for diabetic foot ulcers, which could generate peak sales of $400m+, and is the largest value driver for the stock. We think Derma Sciences’ shares are undervalued based on its revenue growth perspectives and the risked potential of DSC127.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news